Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Spanish drugmaker ROVI's 9M revenue rises on strong CDMO, Okedi sales

By Reuters News


Overview

  • Spain pharmaceutical manufacturer's 9M 2026 operating revenue grew 16% yr/yr

  • Net profit for 9M 2026 rose 67% yr/yr

  • Company completed acquisition of pharmaceutical plant in Phoenix, Arizona


Outlook

  • Company upgrades its 2026 operating revenue guidance

  • Expects operating revenue to increase by a mid-to high-single-digit percentage compared with 2025, versus its previous guidance of growth in the low- to mid-single-digit range

  • Company says outlook upgrade is mainly the result of the stronger expected growth of the CDMO business


Result Drivers

  • CDMO GROWTH - Strong performance in contract development and manufacturing business drove revenue increase

  • OKEDI SALES - Sales of Okedi® rose 29% yr/yr, contributing to overall growth

  • GROSS MARGIN EXPANSION - Margin growth attributed to CDMO, Okedi®, lower LMWH raw material prices and R&D aid


Company press release: Full Story


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

9M Revenue

EUR 610.20 mln

9M Net Income

EUR 162.80 mln

9M EBIT

EUR 198.70 mln

9M EBITDA

EUR 226.60 mln

9M Free Cash Flow

EUR 61.90 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Laboratorios Farmaceuticos Rovi, S.A. is €75.00, about 17.6% above its November 4 closing price of €63.75

  • The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 19 three months ago


Reuters Recommended Reads

  • Nov 3 - Pfizer raises 2026 forecast on strong demand for blood thinner Eliquis

  • Nov 3 - BioNTech's Q3 revenue falls on lower COVID-19 vaccine demand

  • Nov 3 - Ireland's Alkermes Q3 revenue beats on LUMRYZ growth


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.